WILMINGTON,PPD is investing $25 million in Syrrx, a drug development company in California as part of a contract to create oral treatment for diabetes.

Syrrx, which takes its name from seer and RX, has a drug in clinical trials.

The companies will develop and commercialize inhibitors called dipeptidyl peptidase (DP) IV, to combat Type 2 diabetes and other diseases.

The goal is to develop a once- or twice-a-day oral treatment, the companies said in a statement.

In addition to the cash investment, PPD will provide pre-clinical and clinical development resources and will pay for several studies. PPD also will make milestone payments to Syrrx.

The firms said they would share the cost of Phase III trials. If a drug is approved by the FDA, the companies said they will split the profits.

According to PPD, DP4 “plays an important role in regulating insulin levels” and that “orally delivered DP4 inhibitors reduced blood glucose and increased insulin response in patients.”

“These data indicate that small-molecule inhibitors that target DP4 could be potential treatments for major human diseases including type 2 diabetes, obesity, high cholesterol and other forms of metabolic syndrome,” PPD said in a statement.

PPD: www.ppdi.com

Syrrx: www.syrrx.com